Sinopharm Group Co Ltd - Company Profile
Powered by 
All the data and insights you need on Sinopharm Group Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Sinopharm Group Co Ltd Strategy Report
- Understand Sinopharm Group Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Sinopharm Group Catalyst Calendar
Proactively evaluate Sinopharm Group Co Ltd’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Sinopharm Group Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 16 Jul 2021 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 31 Dec 2020 | Commercial Launch (Global) | Sinopharm Group Co Ltd | 1099 | BBIBP-CorV | Infectious Disease | Coronavirus Disease 2019 (COVID-19) | Company Presentation |
| 26 Nov 2020 | Phase I Trial Completion | Beijing Biological Products Research Institute Co Ltd; Beijing Zhong Sheng Hengyi Pharmaceutical Technology Co Ltd; Lanzhou Institute of Biological Products Co Ltd; National Vaccine & Serum Institute; Sinopharm Zhongsheng Biotechnology Research Institute Co Ltd; Zhengzhou University | - | norovirus [strains GI.1 + GII.4] (bivalent) vaccine | Gastrointestinal; Infectious Disease | Gastroenteritis; Norovirus Infections | Clinical Trial Registry |
| 01 Nov 2020 | Phase III Trial Results | Beijing Institute of Biological Products; China National Biotech Group Co Ltd; Fundacion Huesped; Laboratorio ELEA SACIF y A; Sheikh Khalifa Medical City; Sinopharm Group Co Ltd; Whoop Inc | 1099 | BBIBP-CorV | Infectious Disease | Coronavirus Disease 2019 (COVID-19) | Company Press Release |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer